The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country

Mehlika Toy (), Fatih Onder, Ramazan Idilman, Gokhan Kabacam, Jan Richardus, Mithat Bozdayi, Meral Akdogan, Zarife Kuloglu, Aydan Kansu, Solko Schalm and Cihan Yurdaydin

The European Journal of Health Economics, 2012, vol. 13, issue 5, 663-676

Abstract: In a country with considerable amount of active CHB patients, monotherapy with a highly potent third generation drug has the most health-gain, and is cost-effective in both HBeAg-positive and negative in all stages of liver disease. Copyright The Author(s) 2012

Keywords: Chronic hepatitis B; Cost-effectiveness analysis; Antiviral therapy; Turkey; Middle income; I18 (search for similar items in EconPapers)
Date: 2012
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://hdl.handle.net/10.1007/s10198-012-0413-8 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:eujhec:v:13:y:2012:i:5:p:663-676

Ordering information: This journal article can be ordered from
http://www.springer. ... cs/journal/10198/PS2

DOI: 10.1007/s10198-012-0413-8

Access Statistics for this article

The European Journal of Health Economics is currently edited by J.-M.G.v.d. Schulenburg

More articles in The European Journal of Health Economics from Springer, Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().